<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429597</url>
  </required_header>
  <id_info>
    <org_study_id>FaCard06/2011</org_study_id>
    <nct_id>NCT01429597</nct_id>
  </id_info>
  <brief_title>Fabry and Cardiomyopathy (FaCard) Epidemiological Study for the Analysis of Biomarkers and the Clinical Course of Patients With Fabry Disease and the N215S-mutation</brief_title>
  <acronym>FaCard</acronym>
  <official_title>Fabry and Cardiomyopathy (FaCard) Epidemiological Study for the Analysis of Biomarkers and the Clinical Course of Patients With Fabry Disease and the N215S-mutation AN INTERNATIONAL,MULTICENTER, EPIDEMIOLOGICAL STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective and endpoint is the analysis of the long-term course of lyso-Gb3 and its
      clinical correlation to the progression of the cardiomyopathy in N215S-Fabry patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fabry disease is an X-linked lysosomal disorder that leads to excessive deposition of neutral
      glycosphingolipids in the vascular endothelium of several organs in the body. Progressive
      endothelial accumulation of glycosphingolipids accounts for the associated clinical
      abnormalities of skin, eye, kidney, heart, brain, and peripheral nervous system. Fabry
      disease manifesting predominantly in men. Female heterozygotes also present with features of
      Fabry disease. It is suggested that the mean age of hemizygotic men at the onset of
      symptomatic stroke is 29 - 34 years. The mean age of female heterozygotes at the onset of
      symptomatic strokes is 40 - 43 years.In Europe the prevalence of Fabry disease seems to be
      massively underrepresented; actual textbooks describe 1 per 40.000. However, recent data (Lin
      HY, et al., 2009) demonstrate the identification of eight different mutations in the
      alpha-galactosidase A (alpha-Gal A) gene in 110 027 newborns who were screened by assaying
      the alpha-Gal A activity followed by genetic analysis. Hwu and co-workers (2009) have shown
      in 90,288 male newborns screened for Fabry disease that 73 males had GLA gene mutations.
      Surprisingly, 86% had the c.936+919G&gt;A (also called IVS4+919G&gt;A) splice mutation. In
      contrast, screening 81,689 females detected two heterozygotes. Summarizing, newborn screening
      identified a surprisingly high frequency of Taiwanese males with Fabry disease (approximately
      1 in 1,250), 86% having the IVS4+919G&gt;A mutation previously found in later-onset cardiac
      phenotype patients.The late-onset mutation N215S is discussed to be a so-called cardiac
      variant (Perry Elliott, 2006; Eng et al., 1993, Sachdev et al., 2002). The prevalence of most
      mutations is low, i.e. Fabry disease spontaneously and individually inheriting so-called
      private mutations. However, there are some mutations that occur more frequent. Besides for
      instance R112H, A143T and R227X, also N215S belongs to this group (Dobrovolny et al., ASHG
      Abstract, 2008). The enzyme activity is only moderately affected, but hemizygous patients
      display a clearly decreased activity in leucocytes and fibroblasts.

      In 2005, Young and colleagues (Acta Paediatr Suppl.) concluded that Gb3 is not an ideal
      biomarker using the example of N215S. All heterozygotes were unconspicuous and only 50% of
      the examined hemizygotes had increased levels. However, globotraosylceramid (lyso Gb3) seems
      to reveal all (genetically) found patients with a pathologically elevated level (with a mean
      of 1,17ng/ml (females) and 2,43ng/ml (males) respectively).

      In a case study from 2004 (Meehan et al., American Journal of Kidney Diseases) was shown that
      a hemizygous male 75 years of age had a renal manifestation of mild proteinuria and a mildly
      decreased renal function due to high Gb3 accumulation in podocytes, to a lesser extent in
      tubular endothelial cells. Furthermore, he had mild congestive heart failure, a reduced left
      ventricular ejection fraction, and hypercholesterolemia. Thus, it is obvious that in Fabry
      patients with the N215S mutation disease progression can be mono- to oligosymptomatic, but
      show a tendency for the cardiac and renal phenotype rather than classical manifestation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>analysis of the long-term course of lyso-Gb3 and its clinical correlation to the progression of the cardiomyopathy in N215S-Fabry patients</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebrovascular Accident</condition>
  <condition>Stroke, Acute</condition>
  <condition>Cerebral Stroke</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>All Patients with a diagnosis of Fabry disease with N215S</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The laboratory examinations of the blood samples for measuring the lyso-Gb3-level will be
      done at the Laboratory of the Albrecht-Kossel-Institute, University of Rostock in
      collaboration with associated diagnostic laboratory partners. This laboratory offers an
      existing infrastructure, a highly standardized quality of the workflow, a short examination
      time of the samples and a long period of experiences in the assessment of the biological
      impact of mutations and polymorphism, as evidenced recently in the sifap1-study.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All Patients with a diagnosis of Fabry disease with N215S
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients of both gender from 18 years of age with a diagnosis of Fabry disease
             with the mutation N215S

          -  Written informed consent from patient

        Exclusion Criteria:

          -  Patients without a diagnosis of Fabry disease

          -  No written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arndt Rolfs, MD</last_name>
    <phone>49-381-494</phone>
    <phone_ext>9540</phone_ext>
    <email>arndt.rolfs@med.uni-rostock.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Roesner</last_name>
    <phone>49-381-494</phone>
    <phone_ext>4797</phone_ext>
    <email>sabine.roesner@med.uni-rostock.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Roesner</last_name>
      <phone>49-381-494</phone>
      <phone_ext>4797</phone_ext>
      <email>sabine.roesner@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Arndt Rolfs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Arndt Rolfs</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Cerebrovascular Accident</keyword>
  <keyword>Cerebrovascular Accident, Acute</keyword>
  <keyword>Fabry Disease</keyword>
  <keyword>FabryÂ´s Disease</keyword>
  <keyword>Anderson-Fabry Disease</keyword>
  <keyword>CVA (Cerebrovascular Accident)</keyword>
  <keyword>Stroke, Acute</keyword>
  <keyword>Cerebral Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

